
doi: 10.1002/pu.30468
Esketamine nasal spray in combination with a newly initiated antidepressant was more effective than a new antidepressant plus placebo in reducing depressive symptoms in patients with treatment‐resistant depression, a Phase 3 study has found. Esketamine, the S‐enantiomer of ketamine, recently received Food and Drug Administration (FDA) approval for treatment‐resistant depression in adults. Study results were published online May 21 in the American Journal of Psychiatry.
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
